Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc (NASDAQ: THTX) is a specialty biopharmaceutical company advancing therapies for HIV complications and oncology conditions. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely information about FDA-approved HIV treatments like EGRIFTA for lipodystrophy and Trogarzo for multidrug-resistant infections, alongside emerging oncology candidates targeting aggressive cancers. Our curated news collection includes earnings reports, partnership announcements, and research breakthroughs.
Key updates cover three focus areas: commercialized HIV therapies, pipeline progress in oncology, and operational developments across North American/European markets. Content types include clinical trial results, regulatory filings, and executive commentary.
Bookmark this page for structured access to Theratechnologies' latest advancements in niche biopharmaceutical solutions. Verify information directly through company filings and press releases for informed decision-making.
Theratechnologies reported a Q2 2022 revenue growth of 8.3% to $19.3 million, while year-to-date revenue climbed by 13.9% to $37.8 million. The company achieved a significant 21.5% increase in EGRIFTA SV® sales. Key developments include the initiation of the TH1902 Basket Trial and a $100 million non-dilutive term loan to strengthen its financial position. The revised FY2022 revenue guidance is set between $79 million and $82 million, reflecting a positive outlook despite operational challenges.
MONTREAL, July 14, 2022 – Theratechnologies (THTX) announced updates on its TH1902 Phase 1 clinical safety study, confirming a favorable safety profile at 300 mg/m2, consistent with previous animal studies. Early efficacy signs were noted in heavily pretreated patients, with confirmed partial responses in prostate cancer cases. Six major cancer centers are now active trial sites. Notably, TH1902's targeted delivery mechanism shows the potential for significantly increased drug accumulation in cancer cells, promising advancements in treating sortilin-expressing tumors.
Theratechnologies (TSX: TH, NASDAQ: THTX) announced a binding commitment for a non-dilutive term loan of up to $100 million from Marathon Asset Management. The initial draw of $40 million will help retire $30 million of convertible notes due in 2023. This financing aims to strengthen the company's balance sheet and extend its cash runway, supporting the advancement of its oncology pipeline and growth of existing products, EGRIFTA SV and Trogarzo. The loan agreement has a five-year term with several tranches available based on performance milestones.
Theratechnologies has announced a collaborative research project, funded with nearly CAN $2 million, to explore the efficacy and safety of TH1902 for metastatic cancer treatment. The initiative, supported by several organizations including the Quebec Breast Cancer Foundation and MEI, aims to enhance the therapeutic arsenal for patients with hard-to-treat cancers like triple-negative breast cancer. Led by Professor Borhane Annabi at UQAM, this project capitalizes on prior research success and seeks to improve the quality of life for cancer patients.
Theratechnologies (NASDAQ: THTX) announced it will report its second-quarter financial results for fiscal 2022, ending May 31, on July 14, 2022. The company will host a conference call at 8:30 AM ET the same day, led by President and CEO Paul Lévesque, along with other executives. Participants are encouraged to join early to ensure access. Dial-in details and a webcast link will be provided for the call and replay, which will be available until July 21, 2022.
Theratechnologies Inc. (NASDAQ: THTX) appointed Elif McDonald as the new Senior Director of Investor Relations. McDonald brings over 20 years of experience in capital markets and investor relations, particularly in biotech and pharmaceuticals. CEO Paul Lévesque expressed confidence in her ability to enhance investor engagement and raise awareness of the company’s commercial portfolio and research pipeline. This appointment aims to strengthen the company’s visibility and communication strategies in capital markets.
MONTREAL, May 10, 2022 - Theratechnologies (TSX: TH, NASDAQ: THTX) held its annual meeting where shareholders elected Board candidates and appointed KPMG as auditors. Resolutions for a shareholder rights plan and amendments to the share option plan were approved. The company reported successful revenue growth and is building a research pipeline in oncology, aiming for strong returns for shareholders. Chair Dawn Svoronos emphasized the need for a balanced approach between commercial operations and research development for maximizing shareholder value.
Theratechnologies announced the initiation of patient enrollment in a basket trial for TH1902, its investigational peptide drug conjugate aimed at treating solid tumors expressing Sortilin. The established dose for this phase 1b study is 300 mg/m2, which is 1.5 times the therapeutic dose of docetaxel, without dose-limiting toxicities observed. The study will assess the efficacy and safety of TH1902 in various cancers including HR+ Breast Cancer and Melanoma. This development follows promising pre-clinical results suggesting TH1902 could significantly enhance docetaxel delivery into cancer cells.
Theratechnologies (THTX) has announced it will cease commercialization of Trogarzo® in Europe due to unsatisfactory pricing and reimbursement conditions. The company will focus on the North American market and return European rights to TaiMed Biologics within 180 days. This decision involves restructuring its Dublin subsidiary, resulting in an estimated cash charge of US$1.5 to US$2 million and non-cash charges of about US$6.5 million. European sales, which represented less than 2% of overall revenues, will not impact the company's revenue guidance for fiscal year 2022.
Theratechnologies Inc. (NASDAQ: THTX) will present at the Bloom Burton & Co.’s Healthcare Investor Conference 2022 on Tuesday, May 3, 2022, starting at 1:30 PM ET. The event will take place at the Metro Toronto Convention Centre, Track B, featuring 66 leading healthcare companies.
Investors can receive corporate updates and engage in one-on-one meetings with company management. Registration is mandatory for participation. More details are available on Theratechnologies' official website.
FAQ
What is the current stock price of Theratechnologies (THTX)?
What is the market cap of Theratechnologies (THTX)?
